Bridget E. Bunner

Array ( [id] => 15713307 [patent_doc_number] => 20200103419 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-02 [patent_title] => BLOOD BIOMARKERS AND DIAGNOSTIC METHODS FOR SMALL VESSEL DISEASES [patent_app_type] => utility [patent_app_number] => 16/499192 [patent_app_country] => US [patent_app_date] => 2018-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36664 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16499192 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13955655 [patent_doc_number] => 20190054171 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-21 [patent_title] => FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS [patent_app_type] => utility [patent_app_number] => 15/918663 [patent_app_country] => US [patent_app_date] => 2018-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12844 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15918663 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18171768 [patent_doc_number] => 11571461 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-07 [patent_title] => Methods of use of soluble CD24 for treating lupus nephritis [patent_app_type] => utility [patent_app_number] => 16/491708 [patent_app_country] => US [patent_app_date] => 2018-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 27 [patent_no_of_words] => 18638 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16491708 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13357379 [patent_doc_number] => 20180230229 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-16 [patent_title] => STIMULATION VIA TLR4/MD-2 TO REVERSE TYPE 1 DIABETES [patent_app_type] => utility [patent_app_number] => 15/902191 [patent_app_country] => US [patent_app_date] => 2018-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5394 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15902191 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12862360 [patent_doc_number] => 20180179294 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-28 [patent_title] => TOLL-LIKE RECEPTOR 3 ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 15/898112 [patent_app_country] => US [patent_app_date] => 2018-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32072 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15898112 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12862348 [patent_doc_number] => 20180179290 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-28 [patent_title] => ANTIBODY FORMULATION [patent_app_type] => utility [patent_app_number] => 15/895055 [patent_app_country] => US [patent_app_date] => 2018-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10907 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15895055 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13342889 [patent_doc_number] => 20180222984 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-09 [patent_title] => METHODS AND COMPOSITIONS FOR MODULATION OF BLOOD-NEURAL BARRIER [patent_app_type] => utility [patent_app_number] => 15/893925 [patent_app_country] => US [patent_app_date] => 2018-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16657 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15893925 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13297627 [patent_doc_number] => 20180200350 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-19 [patent_title] => Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity [patent_app_type] => utility [patent_app_number] => 15/893644 [patent_app_country] => US [patent_app_date] => 2018-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22582 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15893644 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13297629 [patent_doc_number] => 20180200351 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-19 [patent_title] => Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity. [patent_app_type] => utility [patent_app_number] => 15/893646 [patent_app_country] => US [patent_app_date] => 2018-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22598 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15893646 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13297633 [patent_doc_number] => 20180200353 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-19 [patent_title] => Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity [patent_app_type] => utility [patent_app_number] => 15/893651 [patent_app_country] => US [patent_app_date] => 2018-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22581 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15893651 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13297625 [patent_doc_number] => 20180200349 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-19 [patent_title] => Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity [patent_app_type] => utility [patent_app_number] => 15/893641 [patent_app_country] => US [patent_app_date] => 2018-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22579 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15893641 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13297631 [patent_doc_number] => 20180200352 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-19 [patent_title] => Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity. [patent_app_type] => utility [patent_app_number] => 15/893648 [patent_app_country] => US [patent_app_date] => 2018-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22577 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15893648 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13444151 [patent_doc_number] => 20180273618 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-27 [patent_title] => Combination Therapy For Treatment Of Disease [patent_app_type] => utility [patent_app_number] => 15/889532 [patent_app_country] => US [patent_app_date] => 2018-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51826 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15889532 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16321291 [patent_doc_number] => 10781247 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-22 [patent_title] => Targeted therapeutics based on engineered proteins that bind EGFR [patent_app_type] => utility [patent_app_number] => 15/886118 [patent_app_country] => US [patent_app_date] => 2018-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 17 [patent_no_of_words] => 28889 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15886118 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13428059 [patent_doc_number] => 20180265572 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-20 [patent_title] => MULTIVALENT FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS [patent_app_type] => utility [patent_app_number] => 15/866919 [patent_app_country] => US [patent_app_date] => 2018-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36304 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15866919 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13357347 [patent_doc_number] => 20180230213 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-16 [patent_title] => ANTI-NOTCH3 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 15/864710 [patent_app_country] => US [patent_app_date] => 2018-01-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21730 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15864710 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18351481 [patent_doc_number] => 20230139592 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-04 [patent_title] => SIRP-GAMMA TARGETED AGENTS FOR USE IN THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/470719 [patent_app_country] => US [patent_app_date] => 2017-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29422 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16470719 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12750481 [patent_doc_number] => 20180141994 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-24 [patent_title] => TOLL-LIKE RECEPTOR 2 BINDING EPITOPE AND BINDING MEMBER THERETO [patent_app_type] => utility [patent_app_number] => 15/842044 [patent_app_country] => US [patent_app_date] => 2017-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21496 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15842044 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15726803 [patent_doc_number] => 10611823 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-07 [patent_title] => CD137 binding fibronectin type III domains [patent_app_type] => utility [patent_app_number] => 15/840303 [patent_app_country] => US [patent_app_date] => 2017-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20713 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15840303 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15666441 [patent_doc_number] => 10597438 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-24 [patent_title] => PD-L1 binding fibronectin type III domains [patent_app_type] => utility [patent_app_number] => 15/840281 [patent_app_country] => US [patent_app_date] => 2017-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16871 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15840281 [rel_patent_id] =>[rel_patent_doc_number] =>)